GILD
GILEAD SCIENCES, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$153.07
−2.00%Aug 15, 2026, 07:30 UTC
Benjamin Edwards Inc. reduced its stake in Gilead Sciences, Inc. by 5.0% during the second quarter, selling 6,539 shares and retaining 125,525 shares.
Aug 14, 2026, 16:27 UTC
A U.S. Court of Appeals upheld a preliminary injunction against several AFPs and related businesses, barring them from importing Gilead medications from overseas.
Source:Aug 11, 2026, 20:05 UTC
Gilead Sciences exercised its option to exclusively license a preclinical bispecific program from MacroGenics under their 2022 collaboration agreement, triggering a $10 million payment to MacroGenics.
Source:Aug 11, 2026, 11:24 UTC
Zoomex launched twelve new USDT-margined stock perpetual contracts for UnitedHealth Group, General Electric, JPMorgan Chase, Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Walmart, Coca-Cola, PepsiCo, Mastercard, PayPal Holdings, and Berkshire Hathaway Class B, offering 24/7 long and short trading with up to 25x leverage.
Source:Aug 7, 2026, 03:07 UTC
Merck & Co.'s Ebola vaccine and Gilead Sciences' antiviral drug are set for wider use in eastern Democratic Republic of Congo to combat the fastest-growing Ebola outbreak on record.
Source:Aug 4, 2026, 20:04 UTC
Gilead Sciences reported second-quarter product sales rose 8%, driven by double-digit gains in HIV drugs, but posted a quarterly loss due to acquisition-related costs.
Aug 3, 2026, 17:04 UTC
California's highest court ruled in favor of Gilead Sciences in a 'duty to innovate' case on Monday.
Jul 30, 2026, 09:49 UTC
Viread (09887) announced that the Phase II clinical study of Opatsoumab (Viread™, a PD-L1/4-1BB bispecific antibody, LBL-024) for first-line treatment of advanced biliary tract cancer (BTC) has completed enrollment of all 70 patients.
Source:Jul 14, 2026, 12:48 UTC
Researchers in the Democratic Republic of Congo began enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure treatment for the Bundibugyo Ebola outbreak.
Jul 8, 2026, 00:00 UTC
Aura Biosciences appointed Jeremy Bender as a Class II director effective July 7, 2026.
Jul 6, 2026, 19:41 UTC
Gilead Sciences received FDA approval to expand the label of Trodelvy for first-line metastatic triple-negative breast cancer.
Source:Jun 25, 2026, 10:45 UTC
The U.S. FDA approved Merck's KEYTRUDA and KEYTRUDA QLEX, each in combination with Gilead's Trodelvy, for first-line treatment of PD-L1+ advanced triple-negative breast cancer.
Source:Jun 24, 2026, 16:25 UTC
Gilead Sciences received European Commission approval to expand Trodelvy's label to include first-line treatment of metastatic triple-negative breast cancer.
Source:Jun 23, 2026, 11:45 UTC
The European Commission granted marketing authorization for Gilead Sciences' Trodelvy as a first-line treatment for metastatic triple-negative breast cancer patients not candidates for PD-(L)1 inhibitors.
Source:Jun 15, 2026, 19:46 UTC
The U.S. Food and Drug Administration approved Gilead Sciences' experimental drug Hepcludex for the treatment of chronic hepatitis delta virus.
Source:Jun 12, 2026, 12:30 UTC
Gilead Sciences donated more than 2,000 vials of remdesivir to Uganda to support Ebola response efforts.
Source:Jun 9, 2026, 20:36 UTC
Gilead and Merck end a lung cancer study.
Source:Jun 8, 2026, 20:30 UTC
Merck and Gilead discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 study based on an external Data Monitoring Committee recommendation.
Source:Jun 4, 2026, 20:59 UTC
Gilead Sciences and Lakefront Capital completed the acquisition of Ouro Medicines.
Jun 3, 2026, 16:21 UTC
Gilead Sciences reported positive phase III IDEAL study results for Livdelzi in primary biliary cholangitis patients, showing improved ALP normalization.
Source:
← PreviousPage 2